Position in FATE
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$144,411
-$147,709 QoQ
Shares Held
120,343
-59.6% QoQ
Ownership
0.103%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 0.ToString("F0")%
Shared 100.ToString("F0")%
None 0.ToString("F0")%
Common Shares in FATE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Quadrature Capital Ltd holds $97,315,526 across 122 Biotechnology names. FATE ranks #85 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
85,241 | $28,203,689 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
18,602 | $14,372,649 | |
| 3 | EXEL |
Exelixis, Inc.
|
90,140 | $3,866,104 | |
| 4 | BLTE |
Belite Bio, Inc
|
23,708 | $3,780,003 | |
| 5 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
55,546 | $3,482,734 | |
| 6 | AVTX |
Avalo Therapeutics, Inc.
|
125,195 | $1,869,161 | |
| 7 | ADMA |
Adma Biologics, Inc.
|
204,475 | $1,842,319 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
16,667 | $1,620,865 |
All Filings in FATE
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $144,411 | 120,343 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $292,120 | 298,082 | Shares | Other | 2026-02-17 | |
| 2025-09-30 | $475,469 | 377,357 | Shares | Other | 2025-11-13 | |
| No filing history on record for this holder in this stock. | ||||||